Advertisement
Advertisement

AGMB

AGMB logo

AgomAb Therapeutics NV - ADR

14.50
USD
Sponsored
+1.00
+7.41%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

14.44

-0.06
-0.45%

AgomAb Therapeutics NV - ADR Profile

About

Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with unmet medical need. Agomab Therapeutics NV is based in ANTWERP, Belgium.

Info & Links

CEO

Tim Knotnerus

Headquarters

POSTHOFLEI 1/6
ANTWERPEN, C9 2600, BELGIUM

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.agomab.com

Auditor

Didier Delanoye

Share holders

--

Employees

62

AgomAb Therapeutics NV - ADR Statistics

Valuation Measures

Market Capitalization2

710.89M

Enterprise Value

454.58M

Enterprise Value/EBITDA(ttm)

--

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

0.00%

Return on Assets(ttm)

--

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

--

Gross Profit(ttm)

0.00

EBITDA(ttm)3

0.00

Net Income Available to Common(ttm)

0.00

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

--

52-Week Change

--

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

0.00

% Held by Insiders

--

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

292.97M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

1.32M

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

--

Quick Ratio(mrq)

6.52%

Book Value Per Share(mrq)

--

Cash Flow

Operating Cash Flow Per Share(ytd)

--

Free Cash Flow(ytd)

0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement